These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 31358544)

  • 21. Denosumab treatment is associated with the absence of circulating tumor cells in patients with breast cancer.
    Vetter M; Landin J; Szczerba BM; Castro-Giner F; Gkountela S; Donato C; Krol I; Scherrer R; Balmelli C; Malinovska A; Zippelius A; Kurzeder C; Heinzelmann-Schwarz V; Weber WP; Rochlitz C; Aceto N
    Breast Cancer Res; 2018 Nov; 20(1):141. PubMed ID: 30458879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?
    Dawood S; Broglio K; Valero V; Reuben J; Handy B; Islam R; Jackson S; Hortobagyi GN; Fritsche H; Cristofanilli M
    Cancer; 2008 Nov; 113(9):2422-30. PubMed ID: 18785255
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer.
    Banys-Paluchowski M; Fehm T; Janni W; Aktas B; Fasching PA; Kasimir-Bauer S; Milde-Langosch K; Pantel K; Rack B; Riethdorf S; Solomayer EF; Witzel I; Müller V
    BMC Cancer; 2018 May; 18(1):541. PubMed ID: 29739347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy.
    Bidard FC; Mathiot C; Degeorges A; Etienne-Grimaldi MC; Delva R; Pivot X; Veyret C; Bergougnoux L; de Cremoux P; Milano G; Pierga JY
    Ann Oncol; 2010 Sep; 21(9):1765-1771. PubMed ID: 20233745
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer.
    Wallwiener M; Hartkopf AD; Baccelli I; Riethdorf S; Schott S; Pantel K; Marmé F; Sohn C; Trumpp A; Rack B; Aktas B; Solomayer EF; Müller V; Janni W; Schneeweiss A; Fehm TN
    Breast Cancer Res Treat; 2013 Jan; 137(2):503-10. PubMed ID: 23271327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer.
    Mu Z; Wang C; Ye Z; Rossi G; Sun C; Li L; Zhu Z; Yang H; Cristofanilli M
    Breast Cancer Res Treat; 2017 Oct; 165(3):733-741. PubMed ID: 28687903
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic Impact of Circulating Tumor Cell Detected Using a Novel Fluidic Cell Microarray Chip System in Patients with Breast Cancer.
    Sawada T; Araki J; Yamashita T; Masubuchi M; Chiyoda T; Yunokawa M; Hoshi K; Tao S; Yamamura S; Yatsushiro S; Abe K; Kataoka M; Shimoyama T; Maeda Y; Kuroi K; Tamura K; Sawazumi T; Minami H; Suda Y; Koizumi F
    EBioMedicine; 2016 Sep; 11():173-182. PubMed ID: 27495793
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating tumor cells in newly diagnosed inflammatory breast cancer.
    Mego M; Giordano A; De Giorgi U; Masuda H; Hsu L; Giuliano M; Fouad TM; Dawood S; Ueno NT; Valero V; Andreopoulou E; Alvarez RH; Woodward WA; Hortobagyi GN; Cristofanilli M; Reuben JM
    Breast Cancer Res; 2015 Jan; 17(1):2. PubMed ID: 25572591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer.
    Botteri E; Sandri MT; Bagnardi V; Munzone E; Zorzino L; Rotmensz N; Casadio C; Cassatella MC; Esposito A; Curigliano G; Salvatici M; Verri E; Adamoli L; Goldhirsch A; Nolè F
    Breast Cancer Res Treat; 2010 Jul; 122(1):211-7. PubMed ID: 19967556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis.
    Trapp E; Janni W; Schindlbeck C; Jückstock J; Andergassen U; de Gregorio A; Alunni-Fabbroni M; Tzschaschel M; Polasik A; Koch JG; Friedl TWP; Fasching PA; Haeberle L; Fehm T; Schneeweiss A; Beckmann MW; Pantel K; Mueller V; Rack B; Scholz C;
    J Natl Cancer Inst; 2019 Apr; 111(4):380-387. PubMed ID: 30312434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of circulating tumour cells enumerated after filtration enrichment in early and metastatic breast cancer patients.
    Wong NS; Kahn HJ; Zhang L; Oldfield S; Yang LY; Marks A; Trudeau ME
    Breast Cancer Res Treat; 2006 Sep; 99(1):63-9. PubMed ID: 16541316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients.
    Banys-Paluchowski M; Witzel I; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer EF; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T; Müller V
    Anticancer Res; 2017 Jun; 37(6):3117-3128. PubMed ID: 28551653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial.
    Cabel L; Berger F; Cottu P; Loirat D; Rampanou A; Brain E; Cyrille S; Bourgeois H; Kiavue N; Deluche E; Ladoire S; Campone M; Pierga JY; Bidard FC
    Br J Cancer; 2021 Mar; 124(7):1207-1213. PubMed ID: 33473163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive and prognostic value of folate receptor-positive circulating tumor cells in small cell lung cancer patients treated with first-line chemotherapy.
    Shen J; Zhao J; Jiang T; Li X; Zhao C; Su C; Zhou C
    Oncotarget; 2017 Jul; 8(30):49044-49052. PubMed ID: 28467771
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer.
    Janni WJ; Rack B; Terstappen LW; Pierga JY; Taran FA; Fehm T; Hall C; de Groot MR; Bidard FC; Friedl TW; Fasching PA; Brucker SY; Pantel K; Lucci A
    Clin Cancer Res; 2016 May; 22(10):2583-93. PubMed ID: 26733614
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer.
    Franken B; de Groot MR; Mastboom WJ; Vermes I; van der Palen J; Tibbe AG; Terstappen LW
    Breast Cancer Res; 2012 Oct; 14(5):R133. PubMed ID: 23088337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients.
    Zhang S; Li L; Wang T; Bian L; Hu H; Xu C; Liu B; Liu Y; Cristofanilli M; Jiang Z
    BMC Cancer; 2016 Jul; 16():526. PubMed ID: 27456503
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circulating tumor cells before and during follow-up after breast cancer surgery.
    van Dalum G; van der Stam GJ; Tibbe AG; Franken B; Mastboom WJ; Vermes I; de Groot MR; Terstappen LW
    Int J Oncol; 2015 Jan; 46(1):407-13. PubMed ID: 25339612
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer.
    Zhou J; Dong F; Cui F; Xu R; Tang X
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):825-833. PubMed ID: 28289866
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients.
    Huebner H; Fasching PA; Gumbrecht W; Jud S; Rauh C; Matzas M; Paulicka P; Friedrich K; Lux MP; Volz B; Gass P; Häberle L; Meier-Stiegen F; Hartkopf A; Neubauer H; Almstedt K; Beckmann MW; Fehm TN; Ruebner M
    BMC Cancer; 2018 Feb; 18(1):204. PubMed ID: 29463222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.